As flu season approaches and COVID-19 continues to circulate, vaccination remains one of the most effective ways for people with myositis to protect themselves from serious illness. While concerns about vaccine-related flares are understandable, research and expert guidance consistently support vaccination for individuals with autoimmune diseases.
For those over 65 or with other risk factors, high-dose or adjuvanted flu vaccines may offer better protection. The CDC and American College of Rheumatology recommend inactivated flu vaccines for people with autoimmune conditions, including those on immunosuppressive therapies.
Dr. Victoria Werth, a member of The Myositis Association’s Medical Advisory Board, advises:
“It is important for people to get the stronger flu vaccine if age appropriate. There may be the occasional patient who has a mild flare, but it is rare.”
Regarding COVID-19, the international COVAD study—spanning over 100 countries—has provided valuable insights into vaccine safety for people with idiopathic inflammatory myopathies (IIMs). Findings show that while individuals with active disease or multiple autoimmune conditions may experience more frequent mild adverse events, serious reactions are rare, and hospitalization rates are low. Importantly, the study confirms that COVID-19 vaccines are generally safe and well tolerated in people with myositis, especially those with stable disease.
Given the potential for infections to trigger disease flares or complications, the benefits of vaccination far outweigh the risks. Patients are encouraged to speak with their healthcare providers about the best timing for vaccination, especially if they are on immunosuppressive medications.
Stay protected this season—get your flu and COVID-19 vaccines. Your health is worth it.